Fate Therapeutics (FATE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

FATE Stock Forecast

Fate Therapeutics stock forecast is as follows: an average price target of $5.00 (represents a 201.20% upside from FATE’s last price of $1.66) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

FATE Price Target

The average price target for Fate Therapeutics (FATE) is $5.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 201.20% upside from FATE's last price of $1.66.

FATE Analyst Ratings

Buy

According to 11 Wall Street analysts, Fate Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FATE stock is 0 'Strong Buy' (0.00%), 5 'Buy' (45.45%), 5 'Hold' (45.45%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).

Fate Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 13, 2024	Etzer Darout	BMO Capital	$5.00	$3.37	48.37%	201.20%
Aug 14, 2024	Benjamin Burnett	Stifel Nicolaus	$5.00	$3.27	52.91%	201.20%
Jun 17, 2024	Edward Tenthoff	Piper Sandler	$6.00	$3.60	66.44%	261.45%
May 16, 2024	Debjit Chattopadhyay	H.C. Wainwright	$5.00	$4.24	17.92%	201.20%
May 10, 2024	Edward Tenthoff	Piper Sandler	$4.00	$3.88	3.09%	140.96%
May 10, 2024	Etzer Darout	BMO Capital	$6.00	$3.87	55.24%	261.45%
May 10, 2024	Bill Maughan	Canaccord Genuity	$9.00	$3.90	130.77%	442.17%
Jan 09, 2023		Goldman Sachs	$4.00	$4.40	-9.09%	140.96%
Jan 06, 2023		Morgan Stanley	$8.00	$4.22	89.64%	381.93%
Jan 06, 2023		Piper Sandler	$12.00	$11.00	9.09%	622.89%
Jan 06, 2023		BMO Capital	$7.00	$11.00	-36.36%	321.69%
Jan 05, 2023	Robyn Karnauskas	Truist Financial	$7.00	$11.00	-36.36%	321.69%
Dec 15, 2022	Andrea Tan	Goldman Sachs	$10.00	$15.37	-34.94%	502.41%
Dec 13, 2022		Truist Financial	$46.00	$15.46	197.64%	2671.08%
Dec 13, 2021	Matthew Biegler	Oppenheimer	$135.00	$48.98	175.62%	8032.53%
Nov 08, 2021	Yigal Nochomovitz	Citigroup	$87.00	$60.79	43.12%	5140.96%
Nov 05, 2021	Anthony Butler	Roth Capital	$60.00	$61.42	-2.31%	3514.46%
Oct 25, 2021	Michael Yee	Jefferies	$145.00	$58.16	149.31%	8634.94%
Aug 20, 2021	Edward Tenthoff	Piper Sandler	$113.00	$67.01	68.63%	6707.23%

The latest Fate Therapeutics stock forecast, released on Nov 13, 2024 by Etzer Darout from BMO Capital, set a price target of $5.00, which represents a 48.37% increase from the stock price at the time of the forecast ($3.37), and a 201.20% increase from FATE last price ($1.66).

Fate Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	7
Avg Price Target	-	$5.00	$5.71
Last Closing Price	$1.66	$1.66	$1.66
Upside/Downside	-100.00%	201.20%	243.98%

In the current month, the average price target of Fate Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fate Therapeutics's last price of $1.66. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 18, 2024	Oppenheimer	Perform	Perform	Hold
Nov 13, 2024	BMO Capital	Market Perform	Market Perform	Hold
Aug 14, 2024	Cowen & Co.	Hold	Hold	Hold
Aug 14, 2024	BMO Capital	Market Perform	Market Perform	Hold
Aug 14, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 17, 2024	Sandler O'Neill	Underperform	Underperform	Hold
Jun 17, 2024	Wedbush	Market Perform	Market Perform	Hold
Jun 17, 2024	Piper Sandler	Neutral	Overweight	Upgrade
May 16, 2024	H.C. Wainwright	Neutral	Neutral	Hold
May 10, 2024	Piper Sandler	Neutral	Neutral	Hold
May 10, 2024	BMO Capital	Market Perform	Market Perform	Hold
Mar 19, 2024	Morgan Stanley	Underperform	Underperform	Hold
Mar 19, 2024	Wedbush	Market Perform	Market Perform	Hold
Feb 27, 2024	Wedbush	Neutral	Neutral	Hold
Jan 09, 2023	Goldman Sachs	Sell	Sell	Hold
Jan 08, 2023	Citigroup	Buy	Buy	Hold
Jan 06, 2023	Wells Fargo		Overweight	Initialise
Jan 06, 2023	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Jan 06, 2023	Piper Sandler	Neutral	Neutral	Hold
Jan 06, 2023	Wedbush		Neutral	Downgrade
Jan 06, 2023	Cowen & Co.		Market Perform	Downgrade
Jan 06, 2023	Piper Sandler		Neutral	Downgrade
Jan 06, 2023	BMO Capital	Outperform	Market Perform	Downgrade
Jan 03, 2023	Guggenheim		Neutral	Downgrade
Dec 22, 2022	Oppenheimer		Perform	Downgrade
Dec 15, 2022	Goldman Sachs		Sell	Initialise
Dec 13, 2022	SVB Leerink	Outperform	Outperform	Hold
Nov 16, 2022	Citigroup	Buy	Buy	Hold
Jul 11, 2022	BMO Capital		Outperform	Upgrade
Apr 25, 2022	Cantor Fitzgerald	Overweight	Overweight	Hold

Fate Therapeutics's last stock rating was published by Oppenheimer on Nov 18, 2024. The company gave FATE a "Perform" rating, the same as its previous rate.

Fate Therapeutics Financial Forecast

Fate Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$1.68M	$1.94M	$933.00K	$58.98M	$44.36M	$14.98M	$18.55M	$18.41M	$17.07M	$14.22M	$13.41M	$11.14M	$15.90M	$7.56M	$5.46M	$2.52M	$2.80M	$2.43M
Avg Forecast	$8.12M	$7.29M	$6.55M	$5.88M	$1.30M	$1.18M	$1.18M	$1.18M	$1.62M	$1.24M	$1.33M	$1.66M	$1.54M	$1.55M	$5.41M	$34.42M	$17.88M	$15.28M	$12.54M	$9.01M	$11.31M	$8.10M	$6.75M	$6.58M	$5.02M	$7.26M	$13.97M	$1.75M	$1.79M	$1.75M
High Forecast	$8.12M	$7.29M	$6.55M	$5.88M	$1.30M	$1.18M	$1.18M	$1.18M	$3.54M	$1.24M	$1.33M	$1.66M	$1.81M	$1.57M	$5.41M	$34.42M	$17.88M	$15.28M	$12.54M	$9.01M	$11.31M	$8.10M	$6.75M	$6.58M	$5.02M	$7.26M	$13.97M	$1.75M	$1.79M	$1.75M
Low Forecast	$8.12M	$7.29M	$6.55M	$5.88M	$1.30M	$1.18M	$1.18M	$1.18M	$877.68K	$1.24M	$1.33M	$1.66M	$904.74K	$1.53M	$5.41M	$34.42M	$17.88M	$15.28M	$12.54M	$9.01M	$11.31M	$8.10M	$6.75M	$6.58M	$5.02M	$7.26M	$13.97M	$1.75M	$1.79M	$1.75M
# Analysts	4	4	4	4	3	3	3	5	8	4	6	6	12	9	9	9	5	5	5	5	6	6	6	6	6	3	3	3	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.09%	1.25%	0.17%	1.71%	2.48%	0.98%	1.48%	2.04%	1.51%	1.76%	1.99%	1.69%	3.17%	1.04%	0.39%	1.44%	1.56%	1.39%

Fate Therapeutics's average Quarter revenue forecast for Mar 24 based on 6 analysts is $1.66M, with a low forecast of $1.66M, and a high forecast of $1.66M. FATE's average Quarter revenue forecast represents a -0.93% decrease compared to the company's last Quarter revenue of $1.68M (Dec 23).

Fate Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	8	4	6	6	12	9	9	9	5	5	5	5	6	6	6	6	6	3	3	3	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-38.69M	$-51.28M	$-62.56M	$-24.40M	$-64.42M	$-83.20M	$-80.15M	$-71.71M	$-66.42M	$-41.79M	$-53.97M	$-44.13M	$-52.25M	$-57.91M	$-27.32M	$-32.81M	$-27.14M	$-25.62M
Avg Forecast	$-8.12M	$-7.29M	$-6.55M	$-5.88M	$-1.30M	$-1.18M	$-1.18M	$-1.18M	$-1.62M	$-1.24M	$-1.33M	$-60.40M	$-1.54M	$-1.55M	$-5.41M	$-64.60M	$-67.60M	$-15.28M	$-12.54M	$-69.09M	$-11.31M	$-8.10M	$-6.75M	$-39.00M	$-5.02M	$-7.26M	$-13.97M	$-28.61M	$-1.79M	$-1.75M
High Forecast	$-8.12M	$-7.29M	$-6.55M	$-5.88M	$-1.30M	$-1.18M	$-1.18M	$-1.18M	$-877.68K	$-1.24M	$-1.33M	$-48.32M	$-904.74K	$-1.53M	$-5.41M	$-51.68M	$-54.08M	$-15.28M	$-12.54M	$-55.27M	$-11.31M	$-8.10M	$-6.75M	$-31.20M	$-5.02M	$-7.26M	$-13.97M	$-22.89M	$-1.79M	$-1.75M
Low Forecast	$-8.12M	$-7.29M	$-6.55M	$-5.88M	$-1.30M	$-1.18M	$-1.18M	$-1.18M	$-3.54M	$-1.24M	$-1.33M	$-72.48M	$-1.81M	$-1.57M	$-5.41M	$-77.52M	$-81.13M	$-15.28M	$-12.54M	$-82.91M	$-11.31M	$-8.10M	$-6.75M	$-46.80M	$-5.02M	$-7.26M	$-13.97M	$-34.33M	$-1.79M	$-1.75M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	25.15%	33.03%	11.56%	0.38%	0.95%	5.44%	6.39%	1.04%	5.87%	5.16%	7.99%	1.13%	10.42%	7.97%	1.96%	1.15%	15.12%	14.61%

undefined analysts predict FATE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fate Therapeutics's previous annual EBITDA (undefined) of $NaN.

Fate Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	8	4	6	6	12	9	9	9	5	5	5	5	6	6	6	6	6	3	3	3	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-53.83M	$-45.17M	$-52.76M	$-9.17M	$-48.31M	$-80.73M	$-69.10M	$-56.91M	$-68.62M	$-43.31M	$-55.13M	$-45.09M	$-53.11M	$-58.68M	$-28.07M	$-33.52M	$-28.30M	$-26.61M
Avg Forecast	$-44.98M	$-45.01M	$-45.12M	$-45.14M	$-53.01M	$-52.38M	$-50.72M	$-52.65M	$-51.75M	$-49.05M	$-54.59M	$-63.47M	$-61.50M	$-65.94M	$-69.31M	$-67.89M	$-69.85M	$-105.13M	$-97.39M	$-72.60M	$-78.24M	$-66.89M	$-61.04M	$-39.85M	$-46.17M	$-38.77M	$-31.72M	$-29.22M	$-45.33M	$-44.26M
High Forecast	$-44.98M	$-45.01M	$-45.12M	$-45.14M	$-53.01M	$-52.38M	$-50.72M	$-45.79M	$-45.87M	$-49.05M	$-54.59M	$-50.78M	$-53.95M	$-65.94M	$-69.31M	$-54.31M	$-55.88M	$-105.13M	$-97.39M	$-58.08M	$-78.24M	$-66.89M	$-61.04M	$-31.88M	$-46.17M	$-38.77M	$-31.72M	$-23.38M	$-45.33M	$-44.26M
Low Forecast	$-44.98M	$-45.01M	$-45.12M	$-45.14M	$-53.01M	$-52.38M	$-50.72M	$-57.23M	$-56.45M	$-49.05M	$-54.59M	$-76.17M	$-76.61M	$-65.94M	$-69.31M	$-81.46M	$-83.82M	$-105.13M	$-97.39M	$-87.13M	$-78.24M	$-66.89M	$-61.04M	$-47.82M	$-46.17M	$-38.77M	$-31.72M	$-35.07M	$-45.33M	$-44.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	0.69%	0.76%	0.14%	0.69%	0.77%	0.71%	0.78%	0.88%	0.65%	0.90%	1.13%	1.15%	1.51%	0.89%	1.15%	0.62%	0.60%

Fate Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FATE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Fate Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	8	4	6	6	12	9	9	9	5	5	5	5	6	6	6	6	6	3	3	3	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$17.93M	$18.95M	$22.62M	$21.94M	$21.58M	$21.55M	$20.35M	$20.74M	$16.94M	$15.72M	$12.17M	$12.50M	$10.31M	$8.35M	$7.50M	$7.73M	$6.67M	$6.35M
Avg Forecast	$10.47M	$9.40M	$8.43M	$7.57M	$1.67M	$1.52M	$1.52M	$1.52M	$2.09M	$1.60M	$1.71M	$2.14M	$1.98M	$2.00M	$6.97M	$21.44M	$17.24M	$19.69M	$16.16M	$11.61M	$14.57M	$10.44M	$8.70M	$8.47M	$6.46M	$9.36M	$18.00M	$2.26M	$2.31M	$2.26M
High Forecast	$10.47M	$9.40M	$8.43M	$7.57M	$1.67M	$1.52M	$1.52M	$1.52M	$4.57M	$1.60M	$1.71M	$2.14M	$2.33M	$2.02M	$6.97M	$25.72M	$20.69M	$19.69M	$16.16M	$11.61M	$14.57M	$10.44M	$8.70M	$8.47M	$6.46M	$9.36M	$18.00M	$2.26M	$2.31M	$2.26M
Low Forecast	$10.47M	$9.40M	$8.43M	$7.57M	$1.67M	$1.52M	$1.52M	$1.52M	$1.13M	$1.60M	$1.71M	$2.14M	$1.17M	$1.98M	$6.97M	$17.15M	$13.79M	$19.69M	$16.16M	$11.61M	$14.57M	$10.44M	$8.70M	$8.47M	$6.46M	$9.36M	$18.00M	$2.26M	$2.31M	$2.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	9.05%	9.47%	3.24%	1.02%	1.25%	1.09%	1.26%	1.79%	1.16%	1.51%	1.40%	1.47%	1.60%	0.89%	0.42%	3.42%	2.88%	2.81%

Fate Therapeutics's average Quarter SG&A projection for Mar 24 is $2.14M, based on 6 Wall Street analysts, with a range of $2.14M to $2.14M. The forecast indicates a -88.07% fall compared to FATE last annual SG&A of $17.93M (Dec 23).

Fate Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	8	4	6	6	12	9	9	9	5	5	5	5	6	6	6	6	6	3	3	3	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.00	$-0.09	$-0.50	$-0.83	$-0.71	$-0.59	$-0.72	$-0.45	$-0.58	$-0.48	$-0.61	$-0.68	$-0.35	$-0.44	$-0.37	$-0.40
Avg Forecast	$-0.38	$-0.38	$-0.38	$-0.38	$-0.45	$-0.44	$-0.43	$-0.45	$-0.44	$-0.42	$-0.46	$-0.47	$-0.52	$-0.56	$-0.59	$-0.62	$-0.86	$-0.89	$-0.83	$-0.77	$-0.67	$-0.57	$-0.52	$-0.43	$-0.39	$-0.33	$-0.27	$-0.39	$-0.39	$-0.38
High Forecast	$-0.38	$-0.38	$-0.38	$-0.38	$-0.45	$-0.44	$-0.43	$-0.39	$-0.39	$-0.42	$-0.46	$-0.47	$-0.46	$-0.56	$-0.59	$-0.62	$-0.86	$-0.89	$-0.83	$-0.77	$-0.67	$-0.57	$-0.52	$-0.43	$-0.39	$-0.33	$-0.27	$-0.39	$-0.39	$-0.38
Low Forecast	$-0.38	$-0.38	$-0.38	$-0.38	$-0.45	$-0.44	$-0.43	$-0.49	$-0.48	$-0.42	$-0.46	$-0.47	$-0.65	$-0.56	$-0.59	$-0.62	$-0.86	$-0.89	$-0.83	$-0.77	$-0.67	$-0.57	$-0.52	$-0.43	$-0.39	$-0.33	$-0.27	$-0.39	$-0.39	$-0.38
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.00%	0.15%	0.58%	0.93%	0.86%	0.77%	1.08%	0.79%	1.12%	1.10%	1.55%	2.06%	1.30%	1.13%	0.96%	1.06%

According to undefined Wall Street analysts, Fate Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FATE previous annual EPS of $NaN (undefined).

Fate Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EDIT	Editas Medicine	$1.52	$10.20	571.05%	Buy
PRME	Prime Medicine	$2.91	$17.25	492.78%	Buy
IPSC	Century Therapeutics	$1.17	$5.00	327.35%	Buy
SANA	Sana Bio	$1.91	$8.00	318.85%	Buy
NTLA	Intellia Therapeutics	$13.13	$53.00	303.66%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
FATE	Fate Therapeutics	$1.88	$5.00	165.96%	Buy
VERV	Verve Therapeutics	$5.61	$14.00	149.55%	Buy
RCUS	Arcus Biosciences	$16.08	$31.71	97.20%	Buy
BEAM	Beam Therapeutics	$28.58	$55.00	92.44%	Buy
CRSP	CRISPR Therapeutics	$44.63	$77.50	73.65%	Buy
CRBU	Caribou Biosciences	$1.94	$3.00	54.64%	Buy
ATRA	Atara Biotherapeutics	$10.35	$14.00	35.27%	Sell
BPMC	Blueprint Medicines	$96.48	$122.60	27.07%	Buy

FATE Forecast FAQ

Is Fate Therapeutics a good buy?

Yes, according to 11 Wall Street analysts, Fate Therapeutics (FATE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 45.45% of FATE's total ratings.

What is FATE's price target?

Fate Therapeutics (FATE) average price target is $5 with a range of $5 to $5, implying a 201.20% from its last price of $1.66. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Fate Therapeutics stock go up soon?

According to Wall Street analysts' prediction for FATE stock, the company can go up by 201.20% (from the last price of $1.66 to the average price target of $5), up by 201.20% based on the highest stock price target, and up by 201.20% based on the lowest stock price target.

Can Fate Therapeutics stock reach $2?

FATE's average twelve months analyst stock price target of $5 supports the claim that Fate Therapeutics can reach $2 in the near future.

What are Fate Therapeutics's analysts' financial forecasts?

Fate Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.84M (high $4.84M, low $4.84M), average EBITDA is $-4.836M (high $-4.836M, low $-4.836M), average net income is $-209M (high $-202M, low $-213M), average SG&A $6.23M (high $6.23M, low $6.23M), and average EPS is $-1.773 (high $-1.714, low $-1.811). FATE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $27.84M (high $27.84M, low $27.84M), average EBITDA is $-27.837M (high $-27.837M, low $-27.837M), average net income is $-180M (high $-180M, low $-180M), average SG&A $35.87M (high $35.87M, low $35.87M), and average EPS is $-1.53 (high $-1.53, low $-1.53).

Did the FATE's actual financial results beat the analysts' financial forecasts?

Based on Fate Therapeutics's last annual report (Dec 2023), the company's revenue was $63.53M, beating the average analysts forecast of $42.92M by 48.02%. Apple's EBITDA was $-191M, beating the average prediction of $-73.101M by 160.61%. The company's net income was $-161M, missing the average estimation of $-265M by -39.19%. Apple's SG&A was $81.45M, beating the average forecast of $32.39M by 151.46%. Lastly, the company's EPS was $-0.0016, missing the average prediction of $-2.294 by -99.93%. In terms of the last quarterly report (Dec 2023), Fate Therapeutics's revenue was $1.68M, beating the average analysts' forecast of $1.54M by 8.97%. The company's EBITDA was $-38.687M, beating the average prediction of $-1.538M by 2415.32%. Fate Therapeutics's net income was $-53.833M, missing the average estimation of $-61.5M by -12.47%. The company's SG&A was $17.94M, beating the average forecast of $1.98M by 804.91%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.522 by -99.90%